Literature DB >> 2880918

Secretion of somatostatin and its physiologic function.

S Reichlin.   

Abstract

Somatostatin, initially described as a growth hormone release-inhibitory peptide 14 amino acids in length, has been shown to be one of a family of related peptides. It is ubiquitous in distribution and versatile as a paracrine factor with a potentially important role in the regulation of gut, pancreatic, and nervous system function in addition to its well-recognized influence on the pituitary secretion of growth hormone and thyroid-stimulating hormone. With the development of new super agonists, it has become possible to manipulate the endocrine milieu, to modify gut, pancreatic, and pituitary function, and in the case of several diseases such as acromegaly, intractable diarrhea, and carcinoid, to make a significant advance in therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2880918

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

Review 1.  Classification and functions of enteroendocrine cells of the lower gastrointestinal tract.

Authors:  Ashok R Gunawardene; Bernard M Corfe; Carolyn A Staton
Journal:  Int J Exp Pathol       Date:  2011-04-25       Impact factor: 1.925

2.  Inhibition of gastrin gene expression by somatostatin.

Authors:  P S Karnik; S J Monahan; M M Wolfe
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

Review 3.  Somatostatin and analogues in the treatment of cancer. A review.

Authors:  B M Evers; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

4.  The management of acute and chronic pancreatitis.

Authors:  Peter A Banks; Darwin L Conwell; Phillip P Toskes
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-02

Review 5.  Treatment of pituitary tumors: somatostatin.

Authors:  Maria A Tichomirowa; Adrian F Daly; Albert Beckers
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 6.  Peptide Receptor Radionuclide Therapy in Thyroid Cancer.

Authors:  Sriram Gubbi; Christian A Koch; Joanna Klubo-Gwiezdzinska
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-30       Impact factor: 6.055

7.  Update on management of midgut neuroendocrine tumors.

Authors:  Amir Mehrvarz Sarshekeh; Daniel M Halperin; Arvind Dasari
Journal:  Int J Endocr Oncol       Date:  2016-04-08

8.  Growth hormone therapy in normal short children induces a transitory decrease in plasma growth hormone releasing hormone levels and in human growth hormone responsiveness to exogenous growth hormone releasing hormone.

Authors:  I Gil-Ad; B Klinger; A Pertzelan; B Erster; A Silbergeld; H Talpaz; Z Laron
Journal:  J Endocrinol Invest       Date:  1992-11       Impact factor: 4.256

Review 9.  Cancer stratification by molecular imaging.

Authors:  Justus Weber; Uwe Haberkorn; Walter Mier
Journal:  Int J Mol Sci       Date:  2015-03-04       Impact factor: 5.923

10.  Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells.

Authors:  Kristina B V Døssing; Christina Kjær; Jonas Vikeså; Tina Binderup; Ulrich Knigge; Michael D Culler; Andreas Kjær; Birgitte Federspiel; Lennart Friis-Hansen
Journal:  Genes (Basel)       Date:  2018-07-04       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.